Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Forbes

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Breast Cancer Research and Treatment|May 17, 2012
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancerIvana Sestak, Michelle Harvie, Anthony Howell, et al.
BMC Cancer|April 15, 2014
The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancerKelly A Avery-Kiejda, Stephen G Braye, John F Forbes, et al.
The Lancet. Oncology|December 18, 2007
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, John F Forbes, Jack Cuzick, et al.
The Breast Journal|November 5, 2015
Exploring Decision-Making about Neo-adjuvant Chemotherapy for Breast CancerNicholas Zdenkowski, Phyllis Butow, Sheryl Fewster, et al.
Plos One|April 11, 2019
A macroeconomic assessment of the impact of medical research expenditure: A case study of NIHR Biomedical Research CentresJoel B E Smith, Keith M Channon, Vasiliki Kiparoglou, et al.
Journal of the National Cancer Institute|February 22, 2007
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trialJack Cuzick, John F Forbes, Ivana Sestak, et al.
Plos One|June 16, 2011
Risk-targeted selection of agricultural holdings for post-epidemic surveillance: estimation of efficiency gainsIan G Handel, Barend M de C Bronsvoort, John F Forbes, et al.
Plos One|April 26, 2019
Correction: A macroeconomic assessment of the impact of medical research expenditure: A case study of NIHR Biomedical Research CentresJoel B E Smith, Keith M Channon, Vasiliki Kiparoglou, et al.
The Lancet. Oncology|November 20, 2010
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialJack Cuzick, Ivana Sestak, Michael Baum, et al.
BMC Cancer|February 1, 2014
Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancerKelly A Avery-Kiejda, Stephen G Braye, Andrea Mathe, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Breast Cancer Research and Treatment|May 17, 2012
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancerIvana Sestak, Michelle Harvie, Anthony Howell, et al.
BMC Cancer|April 15, 2014
The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancerKelly A Avery-Kiejda, Stephen G Braye, John F Forbes, et al.
The Lancet. Oncology|December 18, 2007
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, John F Forbes, Jack Cuzick, et al.
The Breast Journal|November 5, 2015
Exploring Decision-Making about Neo-adjuvant Chemotherapy for Breast CancerNicholas Zdenkowski, Phyllis Butow, Sheryl Fewster, et al.
Plos One|April 11, 2019
A macroeconomic assessment of the impact of medical research expenditure: A case study of NIHR Biomedical Research CentresJoel B E Smith, Keith M Channon, Vasiliki Kiparoglou, et al.
Journal of the National Cancer Institute|February 22, 2007
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trialJack Cuzick, John F Forbes, Ivana Sestak, et al.
Plos One|June 16, 2011
Risk-targeted selection of agricultural holdings for post-epidemic surveillance: estimation of efficiency gainsIan G Handel, Barend M de C Bronsvoort, John F Forbes, et al.
Plos One|April 26, 2019
Correction: A macroeconomic assessment of the impact of medical research expenditure: A case study of NIHR Biomedical Research CentresJoel B E Smith, Keith M Channon, Vasiliki Kiparoglou, et al.
The Lancet. Oncology|November 20, 2010
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialJack Cuzick, Ivana Sestak, Michael Baum, et al.
BMC Cancer|February 1, 2014
Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancerKelly A Avery-Kiejda, Stephen G Braye, Andrea Mathe, et al.
Pageof 9